financetom
Business
financetom
/
Business
/
Mastercard Insider Sold Shares Worth $9,781,694, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mastercard Insider Sold Shares Worth $9,781,694, According to a Recent SEC Filing
Mar 6, 2025 1:35 PM

04:10 PM EST, 03/06/2025 (MT Newswires) -- Michael Miebach, Director, President & CEO, on March 05, 2025, sold 17,664 shares in Mastercard ( MA ) for $9,781,694. Following the Form 4 filing with the SEC, Miebach has control over a total of 100,646 Class A common shares of the company, with 100,646 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1141391/000114139125000052/xslF345X05/wk-form4_1741294973.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ingram Micro Wins Two Patents in the US for B2B Xvantage Platform
Ingram Micro Wins Two Patents in the US for B2B Xvantage Platform
Mar 11, 2026
07:14 AM EDT, 03/11/2026 (MT Newswires) -- Ingram Micro ( INGM ) said Wednesday that it has been awarded two US patents for proprietary technologies built into its Xvantage business-to-business platform. The first patent covers dynamic stock-keeping unit technology that automatically updates product identifiers with real-time inventory and pricing to bypass traditional catalog size limitations, the company said. The second...
Johnson & Johnson Says FDA Approved Monthly Dosing of Rybrevant Faspro for EGFR-Mutated Lung Cancer
Johnson & Johnson Says FDA Approved Monthly Dosing of Rybrevant Faspro for EGFR-Mutated Lung Cancer
Mar 11, 2026
08:38 AM EST, 02/17/2026 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Tuesday that the US Food and Drug Administration has approved a simplified once-monthly dosing schedule for Rybrevant Faspro in combination with Lazcluze for first-line treatment of EGFR-mutated advanced non-small cell lung cancer. The new schedule provides outcomes consistent with the previously approved bi-weekly subcutaneous regimen, the...
OppFi Q4 Adjusted Earnings, Revenue Rise; Full-Year 2026 Guidance Issued
OppFi Q4 Adjusted Earnings, Revenue Rise; Full-Year 2026 Guidance Issued
Mar 11, 2026
07:14 AM EDT, 03/11/2026 (MT Newswires) -- OppFi ( OPFI ) reported Q4 adjusted earnings Wednesday of $0.30 per share, up from $0.23 a year earlier. Four analysts polled by FactSet expected $0.28. Revenue for the quarter ended Dec. 31 was $159.3 million, up from $135.7 million a year earlier. Four analysts expected revenue of $159.8 million. The company said...
MCF Energy Provides Update on Welchau-1 Testing; Says Well Recovers Gas At Surface During Unloading Operations
MCF Energy Provides Update on Welchau-1 Testing; Says Well Recovers Gas At Surface During Unloading Operations
Mar 11, 2026
08:39 AM EST, 02/17/2026 (MT Newswires) -- MCF Energy ( MCFNF ) on Monday reported initial results from the resumption of testing of the Reifling Formation at the Welchau-1 well in Austria. In a statement the company noted that the 128-meter thick Reifling Formation is the shallowest of four carbonate reservoirs intersected at Welchau-1. It added that the well was...
Copyright 2023-2026 - www.financetom.com All Rights Reserved